| Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry WH Guo, X Qi, X Yu, Y Liu, CI Chung, F Bai, X Lin, D Lu, L Wang, J Chen, ... Nature communications 11 (1), 4268, 2020 | 164 | 2020 |
| Discovery of novel 2, 6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors W Xing, Y Fu, Z Shi, D Lu, H Zhang, Y Hu European Journal of Medicinal Chemistry 63, 95-103, 2013 | 66 | 2013 |
| A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation YJ Wang, D Lu, YB Xu, WQ Xing, XK Tong, GF Wang, CL Feng, PL He, ... Antimicrobial agents and chemotherapy 59 (11), 7061-7072, 2015 | 61 | 2015 |
| Design, synthesis, and biological evaluation of the first c-Met/HDAC inhibitors based on pyridazinone derivatives D Lu, J Yan, L Wang, H Liu, L Zeng, M Zhang, W Duan, Y Ji, J Cao, ... ACS Medicinal Chemistry Letters 8 (8), 830-834, 2017 | 46 | 2017 |
| Targeted protein degradation via lysosomes RR Paudel, D Lu, S Roy Chowdhury, EY Monroy, J Wang Biochemistry 62 (3), 564-579, 2022 | 39 | 2022 |
| Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors X Lv, X Lu, J Cao, Q Luo, Y Ding, F Peng, A Pataer, D Lu, D Han, ... Science 381 (6662), eabn4180, 2023 | 36 | 2023 |
| Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis W Xing, J Ai, S Jin, Z Shi, X Peng, L Wang, Y Ji, D Lu, Y Liu, M Geng, Y Hu European journal of medicinal chemistry 95, 302-312, 2015 | 33 | 2015 |
| Copper(I)-Mediated Cascade Reactions: An Efficient Approach to the Synthesis of Functionalized Benzofuro[3,2-d]pyrimidines B Chao, S Lin, Q Ma, D Lu, Y Hu Organic letters 14 (9), 2398-2401, 2012 | 29 | 2012 |
| Applications of covalent chemistry in targeted protein degradation D Lu, X Yu, H Lin, R Cheng, EY Monroy, X Qi, MC Wang, J Wang Chemical Society Reviews 51 (22), 9243-9261, 2022 | 28 | 2022 |
| Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase Y Liu, S Jin, X Peng, D Lu, L Zeng, Y Sun, J Ai, M Geng, Y Hu European Journal of Medicinal Chemistry 108, 322-333, 2016 | 27 | 2016 |
| Discovery of phthalazinone derivatives as novel hepatitis B virus capsid inhibitors W Chen, F Liu, Q Zhao, X Ma, D Lu, H Li, Y Zeng, X Tong, L Zeng, J Liu, ... Journal of Medicinal Chemistry 63 (15), 8134-8145, 2020 | 24 | 2020 |
| Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors D Lu, J Liu, Y Zhang, F Liu, L Zeng, R Peng, L Yang, H Ying, W Tang, ... European Journal of Medicinal Chemistry 145, 328-337, 2018 | 21 | 2018 |
| Optimization and synthesis of pyridazinone derivatives as novel inhibitors of hepatitis B virus by inducing genome-free capsid formation D Lu, F Liu, W Xing, X Tong, L Wang, Y Wang, L Zeng, C Feng, L Yang, ... ACS infectious diseases 3 (3), 199-205, 2017 | 19 | 2017 |
| Design and synthesis of novel benzo [d] oxazol-2 (3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors D Lu, A Shen, Y Liu, X Peng, W Xing, J Ai, M Geng, Y Hu European journal of medicinal chemistry 115, 191-200, 2016 | 17 | 2016 |
| Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors Y Liu, X Peng, X Guan, D Lu, Y Xi, S Jin, H Chen, L Zeng, J Ai, M Geng, ... European Journal of Medicinal Chemistry 126, 122-132, 2017 | 15 | 2017 |
| Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development X Yu, WH Guo, H Lin, R Cheng, EY Monroy, F Jin, L Ding, D Lu, X Qi, ... Current research in chemical biology 2, 100029, 2022 | 12 | 2022 |
| Development of improved SRC-3 inhibitors as breast cancer therapeutic agents L Qin, J Chen, D Lu, P Jain, Y Yu, D Cardenas, X Peng, X Yu, J Xu, ... Endocrine-related cancer 28 (10), 657-670, 2021 | 12 | 2021 |
| Lysineless HiBiT and NanoLuc tagging systems as alternative tools for monitoring targeted protein degradation H Lin, K Riching, MP Lai, D Lu, R Cheng, X Qi, J Wang ACS Medicinal Chemistry Letters 15 (8), 1367-1375, 2024 | 6 | 2024 |
| Development of Biochemical and Cellular Probes to Study RIPK1 Target Engagement X Yu, H Lin, F Li, J Wang, D Lu ACS Medicinal Chemistry Letters, 2024 | 3 | 2024 |
| Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy D Lu, J Chen, L Qin, I Bijou, P Yi, F Li, X Song, KR MacKenzie, X Yu, ... Journal of medicinal chemistry 67 (7), 5333-5350, 2024 | 1 | 2024 |
